Cargando…
The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening
BACKGROUND: Alzheimer disease (AD) is a progressive neurodegenerative disorder affecting the elderly with a prevalence of 7.1% in women and 3.3% in men. Sex-related patterns have been reported in prognosis, biomarker status, and risk factors. Despite this, the interaction of sex has received limited...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098013/ https://www.ncbi.nlm.nih.gov/pubmed/33952308 http://dx.doi.org/10.1186/s13195-021-00833-4 |
_version_ | 1783688425771106304 |
---|---|
author | Rosende-Roca, Maitee Abdelnour, Carla Esteban, Ester Tartari, Juan Pablo Alarcon, Emilio Martínez-Atienza, Juliana González-Pérez, Antonio Sáez, María E. Lafuente, Asunción Buendía, Mar Pancho, Ana Aguilera, Nuria Ibarria, Marta Diego, Susana Jofresa, Sara Hernández, Isabel López, Rogelio Gurruchaga, Miren Jone Tárraga, Lluís Valero, Sergi Ruiz, Agustín Marquié, Marta Boada, Mercè |
author_facet | Rosende-Roca, Maitee Abdelnour, Carla Esteban, Ester Tartari, Juan Pablo Alarcon, Emilio Martínez-Atienza, Juliana González-Pérez, Antonio Sáez, María E. Lafuente, Asunción Buendía, Mar Pancho, Ana Aguilera, Nuria Ibarria, Marta Diego, Susana Jofresa, Sara Hernández, Isabel López, Rogelio Gurruchaga, Miren Jone Tárraga, Lluís Valero, Sergi Ruiz, Agustín Marquié, Marta Boada, Mercè |
author_sort | Rosende-Roca, Maitee |
collection | PubMed |
description | BACKGROUND: Alzheimer disease (AD) is a progressive neurodegenerative disorder affecting the elderly with a prevalence of 7.1% in women and 3.3% in men. Sex-related patterns have been reported in prognosis, biomarker status, and risk factors. Despite this, the interaction of sex has received limited attention, with AD trials persistently recruiting lower numbers of women than the population distribution and a lack of information on the sex-disaggregated effects of anti-dementia therapies. This is the first study aiming to identify the role of sex in the selection for screening in AD clinical trials. METHODS: This cross-sectional study provides a comprehensive analysis of screening eligibility according to a set of pre-selection criteria currently applied at Fundació ACE memory clinic for a more efficient trial screening process. A cohort of 6667 women and 2926 men diagnosed with AD dementia (55%) or mild cognitive impairment (45%) was analyzed. We also assessed the frequencies of men and women effectively screened for trial enrolment over a period of 10 years. Additionally, data from AddNeuroMed study was used to explore trends in eligibility based on the education criteria. RESULTS: Women showed a significantly lower chance of being eligible for screening than men (OR = 1.26; p < 0.01). This imbalance was confirmed by a lower frequency of women screened for enrolment compared to the study population (63.0% vs. 69.5%). Education was revealed as the key criterion contributing to this unbalance, with men showing over twice the chance of being screened compared with women (OR = 2.25, p < 0.01). Education-based differences were greater in earlier born patients, but the gap narrowed and achieved balance with increasing year of birth. This observation was replicated using data from other European populations included in AddNeuroMed study. Comorbidity was the most limiting criterion with sex differences in frequencies and significant discrimination against the selection of men (OR = 0.86, p < 0.01). CONCLUSIONS: The large number of low-educated elderly women with AD demands for a sex-focused approach in clinical research. New assessment tools insensitive to education level should be developed to enable a proportional representation of women. Although this gender education gap is mostly inexistent in developed countries, economic or cultural factors may lead to different scenarios in other regions. Overlooking the impact of sex may lead to a handicap in AD research with a direct adverse impact on women’s health. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-021-00833-4. |
format | Online Article Text |
id | pubmed-8098013 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-80980132021-05-05 The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening Rosende-Roca, Maitee Abdelnour, Carla Esteban, Ester Tartari, Juan Pablo Alarcon, Emilio Martínez-Atienza, Juliana González-Pérez, Antonio Sáez, María E. Lafuente, Asunción Buendía, Mar Pancho, Ana Aguilera, Nuria Ibarria, Marta Diego, Susana Jofresa, Sara Hernández, Isabel López, Rogelio Gurruchaga, Miren Jone Tárraga, Lluís Valero, Sergi Ruiz, Agustín Marquié, Marta Boada, Mercè Alzheimers Res Ther Research BACKGROUND: Alzheimer disease (AD) is a progressive neurodegenerative disorder affecting the elderly with a prevalence of 7.1% in women and 3.3% in men. Sex-related patterns have been reported in prognosis, biomarker status, and risk factors. Despite this, the interaction of sex has received limited attention, with AD trials persistently recruiting lower numbers of women than the population distribution and a lack of information on the sex-disaggregated effects of anti-dementia therapies. This is the first study aiming to identify the role of sex in the selection for screening in AD clinical trials. METHODS: This cross-sectional study provides a comprehensive analysis of screening eligibility according to a set of pre-selection criteria currently applied at Fundació ACE memory clinic for a more efficient trial screening process. A cohort of 6667 women and 2926 men diagnosed with AD dementia (55%) or mild cognitive impairment (45%) was analyzed. We also assessed the frequencies of men and women effectively screened for trial enrolment over a period of 10 years. Additionally, data from AddNeuroMed study was used to explore trends in eligibility based on the education criteria. RESULTS: Women showed a significantly lower chance of being eligible for screening than men (OR = 1.26; p < 0.01). This imbalance was confirmed by a lower frequency of women screened for enrolment compared to the study population (63.0% vs. 69.5%). Education was revealed as the key criterion contributing to this unbalance, with men showing over twice the chance of being screened compared with women (OR = 2.25, p < 0.01). Education-based differences were greater in earlier born patients, but the gap narrowed and achieved balance with increasing year of birth. This observation was replicated using data from other European populations included in AddNeuroMed study. Comorbidity was the most limiting criterion with sex differences in frequencies and significant discrimination against the selection of men (OR = 0.86, p < 0.01). CONCLUSIONS: The large number of low-educated elderly women with AD demands for a sex-focused approach in clinical research. New assessment tools insensitive to education level should be developed to enable a proportional representation of women. Although this gender education gap is mostly inexistent in developed countries, economic or cultural factors may lead to different scenarios in other regions. Overlooking the impact of sex may lead to a handicap in AD research with a direct adverse impact on women’s health. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-021-00833-4. BioMed Central 2021-05-05 /pmc/articles/PMC8098013/ /pubmed/33952308 http://dx.doi.org/10.1186/s13195-021-00833-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Rosende-Roca, Maitee Abdelnour, Carla Esteban, Ester Tartari, Juan Pablo Alarcon, Emilio Martínez-Atienza, Juliana González-Pérez, Antonio Sáez, María E. Lafuente, Asunción Buendía, Mar Pancho, Ana Aguilera, Nuria Ibarria, Marta Diego, Susana Jofresa, Sara Hernández, Isabel López, Rogelio Gurruchaga, Miren Jone Tárraga, Lluís Valero, Sergi Ruiz, Agustín Marquié, Marta Boada, Mercè The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening |
title | The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening |
title_full | The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening |
title_fullStr | The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening |
title_full_unstemmed | The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening |
title_short | The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening |
title_sort | role of sex and gender in the selection of alzheimer patients for clinical trial pre-screening |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098013/ https://www.ncbi.nlm.nih.gov/pubmed/33952308 http://dx.doi.org/10.1186/s13195-021-00833-4 |
work_keys_str_mv | AT rosenderocamaitee theroleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT abdelnourcarla theroleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT estebanester theroleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT tartarijuanpablo theroleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT alarconemilio theroleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT martinezatienzajuliana theroleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT gonzalezperezantonio theroleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT saezmariae theroleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT lafuenteasuncion theroleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT buendiamar theroleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT panchoana theroleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT aguileranuria theroleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT ibarriamarta theroleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT diegosusana theroleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT jofresasara theroleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT hernandezisabel theroleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT lopezrogelio theroleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT gurruchagamirenjone theroleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT tarragalluis theroleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT valerosergi theroleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT ruizagustin theroleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT marquiemarta theroleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT boadamerce theroleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT rosenderocamaitee roleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT abdelnourcarla roleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT estebanester roleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT tartarijuanpablo roleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT alarconemilio roleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT martinezatienzajuliana roleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT gonzalezperezantonio roleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT saezmariae roleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT lafuenteasuncion roleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT buendiamar roleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT panchoana roleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT aguileranuria roleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT ibarriamarta roleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT diegosusana roleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT jofresasara roleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT hernandezisabel roleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT lopezrogelio roleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT gurruchagamirenjone roleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT tarragalluis roleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT valerosergi roleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT ruizagustin roleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT marquiemarta roleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening AT boadamerce roleofsexandgenderintheselectionofalzheimerpatientsforclinicaltrialprescreening |